New AmsterdamPharma
New AmsterdamPharma raises $453M Series at $2B valuation
New AmsterdamPharma: Series Funding Round
New AmsterdamPharma has successfully raised $453M in Series funding, reaching a valuation of $2B.
Company Overview
Developing novel cholesterol treatment drug for cardiovascular disease
Funding Details
The Series round was led by RA Capital, with participation from RTW Investments.
Company Information
- Headquarters: Amsterdam, Netherlands
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
New AmsterdamPharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series
- RTW Investments: Verified investor in Series
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started